New immunotherapeutic approach takes aim at cancer’s enzyme shield
Immunotherapies have transformed the landscape of cancer treatment by allowing physicians to alter or augment patients’ immune response to better attack malignant tumors. But some tumors — known as “cold tumors” — fly under the immune system’s radar. Checkpoint inhibitors, which are the basis of many immunotherapies, don’t work well against them. A team of…